Effect of isradipine and atenolol on lung function in patients with mild essential hypertension.
Twenty-six hypertensive patients took part in an open, randomized, parallel-group pilot study of the effects of a nine-week treatment period with the calcium antagonist isradipine and the beta 1-blocking agent atenolol. The mean dosage in the isradipine group was 7.9 +/- 3.5 mg/day, and 69.2 +/- 43.5 mg/day in the atenolol group. A significant reduction of the arterial blood pressure was seen with both treatment regimens. Lung volumes and airways resistance remained unchanged, but, in the atenolol-treated group, the linear relationship between alveolar pressure and airways resistance at the lower lung volumes during forced expiration at 25% of forced vital capacity was affected by a shift to higher airways resistance. This change can be interpreted as an early sign of altered air-flow behavior in the small airways in subjects susceptible to beta-adrenoceptor blockade. The calcium antagonist isradipine did not produce changes in any parameters of lung function in this group of patients.
Reiterer
W
W
Department of Internal Medicine I, Policlinic, Vienna, Austria.
Meisner
W
W
D000328:Adult; D000368:Aged; D000403:Airway Resistance / Q000187:drug effects; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001262:Atenolol / Q000494:pharmacology* / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D017275:Isradipine; D008168:Lung / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D011725:Pyridines; D001262:Atenolol; D017275:Isradipine